Exclusive agreement represents significant
initial milestone related to Khiron´s strategy of meeting the
medical needs of 4 million palliative care patients in Latin America
TORONTO, Oct. 26, 2018 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), an integrated medical cannabis company with its core
operations in Colombia, announced
today that the Company has signed an exclusive agreement with the
Colombian Association of Palliative Care (ACCP), the leading
network of pain and palliative care specialists in Colombia.
The Latin American Association of Palliative Care (ALCP)
estimates 4 million people need palliative care treatment within
the Latin American market. This agreement forms the initial step
towards addressing the medical needs of these individuals and
enables Khiron to provide doctors and caregivers with direct access
to specialized e-learning platforms, information, research, and
educational resources about extract-based medical cannabis
treatment alternatives. As part of this agreement, Khiron will be
the exclusive medical cannabis company marketing to, and
participating in, ACCP events and activities in Colombia.
Dr. Maria Fernanda Arboleda,
Medical Director of Khiron stated, "As a pain and palliative care
physician, I have learned from my clinical experience that medical
cannabis can be utilized effectively as a complementary therapy in
reducing pain and related symptoms of palliative care patients.
This important relationship with the Colombian Association of
Palliative Care will allow us to support the use of medical
cannabis in this population and improve the standards of care and
patients´ safety in Colombia."
Dr. Claudia Buitrago, President
of the ACCP stated, "We are convinced that working with Khiron will
bring educational tools that are fundamental to our medical
associates being able to prescribe medical cannabis and allows them
to have a higher degree of confidence that their recommendations
are responsible and informed."
The field of palliative care in Colombia is at the development stage. Doctors,
staff and interdisciplinary teams are working to inform and train
specialist care providers, with the objective of reducing the pain
and associated symptoms of palliative care patients. The recent
International Palliative Care Congress, held in Medellin, Colombia, attracted more than 400
doctors and specialists in pain and palliative care, and included a
presentation by Dr. Arboleda.
Dr. Maria Fernanda Arboleda is
the co-author of 'Cannabis in Palliative Care: current
challenges and practical recommendations', a comprehensive
analysis of the role of Cannabinoid-based medicines in palliative
care treatment. This review, which was recently published in the
Annals of Palliative Medicine, can be found at
http://apm.amegroups.com/article/view/20097/21242
About The Colombian Association of Palliative Care
(ACCP)
Founded in 1996, The Palliative Care Association of Colombia is an non-profit interdisciplinary
association of qualified professionals that have experience in the
clinical aspects, research, and organization of Palliative Care
with a powerful drive to come together to work towards the
development and the implementation of palliative care in all levels
of health care in Colombia.
The ACCP leads changes in palliative care access, and provides
scientific and humanized quality care, providing all universities
with palliative care training programs, as well as in undergraduate
medicine, nursing and psychology. For information visit
www.paliativoscolombia.org
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB: KHRNF,
Frankfurt: A2JMZC) ("Khiron" or
the "Company") is positioned to be the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both tetrahydrocannabinol (THC) and
cannabidiol (CBD) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis company to trade
on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.